Organigram Global Inc. has made a significant move in the cannabis industry by announcing its acquisition of Aurora Cannabis Inc. for C$7.80 per share. This strategic acquisition aims to create a global leader in the cannabis market, combining the strengths of both companies to enhance their operational capabilities and market presence.

The deal, announced on November 3, 2026, values Aurora at approximately C$561 million on a fully diluted equity basis. It represents a 93% premium to Aurora's unaffected share price as of August 10, 2026, and a 21% premium to the value of a hostile bid from Curaleaf Holdings, which was unanimously rejected by Aurora's board.

Background

Organigram Global Inc. (NASDAQ: OGI), incorporated in Canada, operates within the pharmaceutical preparations sector (SIC: 2834). The company has been actively involved in the cannabis market, focusing on the production and distribution of cannabis products. Recent filings show that Organigram has been engaged in various strategic initiatives to expand its footprint in the industry.

What the Filing Says

The filing details the arrangement agreement under which Organigram will acquire all outstanding common shares of Aurora. The transaction provides Aurora shareholders with options to receive cash, Organigram shares, or a combination of both. The filing states, "The Transaction provides Aurora shareholders with compelling immediate value, meaningful choice in how they receive their consideration, and the opportunity for continued participation in the future growth and value creation of the combined company."

Impact

This acquisition is expected to significantly impact both companies and their shareholders. Aurora shareholders will have the flexibility to choose how they receive their compensation, which could enhance their engagement with the new entity. The combined company will possess a stronger market position, with expanded capabilities across Canada, Europe, and Australia, benefiting from Organigram's established recreational cannabis leadership and Aurora's global medical cannabis platform.

What's Next

The transaction is subject to court approval under the Business Corporations Act (British Columbia) and requires the approval of both companies' shareholders. Further details regarding the timeline for these approvals were not available in the SEC filing.

As the cannabis industry continues to evolve, this merger positions Organigram and Aurora to better meet the growing global demand for cannabis products, leveraging their combined resources and expertise to drive long-term profitable growth.